Hunan ER-KANG Pharmaceutical:Quality-consistency evaluations may hinder market share gains of starch capsules

类别:公司研究 机构:瑞银证券有限责任公司 研究员:Fengzhan Zhang,Bing Zhao,Na Lin 日期:2016-12-26

Cutting mid-term ROIC by 5pptWe believe quality-consistency evaluations will affect the progress of Er-Kang's starchcapsules in capturing share from traditional gelatin capsules. The auxiliary materials andtechnologies used to make preparations, including the type of capsule used, can impactwhether a pharmaceutical preparation is able to pass quality-consistency evaluations.

    With this in mind, we think drug makers may avoid switching to this new product,instead preferring to conservatively stick with the gelatin capsules that have been inwidespread use for over 50 years. We therefore estimate that replacement of gelatincapsules with Er-Kang's starch capsules may lose momentum in China, which leads usto cut our mid-term ROIC by 5ppt and lower our PT to Rmb17.84.

    Controlling shareholder to trim stake by up to 9.66% of outstanding sharesOn 7 December, the company announced that Mr. Fangwen Shuai (its controllingshareholder and effective controller) and Ms. Zaiyun Cao, who acts in concert with Mr.

    Shuai, plan to trim their stake in the company by no more than 9.66% of totaloutstanding shares, bringing their combined stake to 36.83%, with the action to becompleted within six months of 12 December.

    We remain optimistic on long-term potential of starch capsulesEr-kang's starch capsule series posted revenue of Rmb683m in H116, up 161.09%YoY. We are positive on the use of starch capsules in the pharmaceutical and foodsectors, given starch capsules' advantages over gelatin capsules (better safety andstability) and our view that replacement of gelatin capsules with starch capsules is along-term trend. Moreover, Er-Kang is the world's only company to have successfullycommercialised starch capsules, and we expect the company will leverage its starchcapsules to gradually expand into the downstream capsule drug preparation market.

    Valuation: Lowering PT to Rmb17.84; maintain Buy ratingWe are lowering our DCF-derived PT by 9.1% to Rmb17.84 (WACC 7.9%), implying35x 2017E PE, while our Buy rating remains unchanged.

股票代码 股票名称 最新价(元) 涨跌额(元) 涨跌幅(%) 成交额(万元) 成交量(手)
300267 @nn@ @n@ @c@ @cc@ @v@ @t@



伊利股份 买入 -- 研报
光明乳业 持有 -- 研报
新乳业 买入 -- 研报
东方日升 买入 14.00 研报
中国国航 买入 -- 研报
上海机场 买入 -- 研报
顺丰控股 买入 -- 研报
韵达股份 买入 -- 研报
格力电器 买入 70.84 研报
海尔智家 买入 17.94 研报
美的集团 买入 60.30 研报


新乳业 0 0 研报
光明乳业 0.21 0.25 研报
伊利股份 0.95 1.08 研报
东方日升 0.94 0.17 研报
顺丰控股 0.42 0.66 研报
上海机场 0.74 0.82 研报
韵达股份 0.18 0.18 研报
海尔智家 1.36 1.15 研报
美的集团 0 0.00 研报
格力电器 1.84 2.20 研报
光威复材 0 0 研报


五粮液 36 持有 持有
万科A 33 买入 买入
隆基股份 31 买入 买入
泸州老窖 31 持有 买入
伊利股份 29 持有 买入
长安汽车 29 买入 买入
比亚迪 29 持有 持有
中国国旅 28 持有 持有
宋城演艺 28 持有 持有
三一重工 27 持有 持有
中信证券 26 持有 买入
保利地产 26 买入 买入
万华化学 26 买入 持有
格力电器 26 买入 买入
亿纬锂能 26 持有 买入
当升科技 26 持有 买入
晶盛机电 26 持有 中性


电子信息 561 85 326
汽车制造 413 35 223
电子器件 389 51 242
建筑建材 372 45 196
机械行业 339 43 138
金融行业 331 26 160
化工行业 284 47 117
酿酒行业 281 16 154
生物制药 268 44 173
房地产 242 29 158
交通运输 238 26 114
钢铁行业 225 30 118
家电行业 204 14 138
食品行业 200 25 70
煤炭行业 185 31 83
商业百货 176 31 103
酒店旅游 165 20 54